A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.

Authors

null

Roberto Pili

University at Buffalo, Buffalo, NY

Roberto Pili , Nabil Adra , Theodore F. Logan , Heather Burney , Michael B. Atkins

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03552380

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 668)

DOI

10.1200/JCO.2023.41.6_suppl.668

Abstract #

668

Poster Bd #

G19

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

First Author: Jianbo Wang

First Author: Alona Zer

First Author: Patrick Walsh McGarrah